Explanipedia

Unbiased high-throughput screening of drug-repurposing libraries identifies small-molecule inhibitors of clot retraction Open

Lorena Buitrago, Miriam-Rose Menezes, Chloe S. Larson, Jihong Li, Thomas Kartika , et al. · 2024

Platelet clot retraction, the ultimate phase of platelet thrombus formation, is critical for clot stabilization. It requires functional αIIbβ3 receptors, fibrin, and the integrated actions of the actin-myosin contractile and cytoskeletal s…

498 Bruton’s tyrosine kinase (BTK) inhibitors impede platelet aggregation but not adhesion to collagen. Open

Thomas Kartika, Lorena Buitrago, Jihong Li, Barry S. Coller · 2024

OBJECTIVES/GOALS: The research objectives of this project are to elucidate the effects of Bruton’s tyrosine kinase inhibitors (BTKi) of varying target specificity on platelet function with regard to platelet aggregation, adhesion, spreadin…

Emicizumab in two patients with acquired haemophilia A – case report Open

Milly Zhao, Thomas Kartika, Corey Witenko, Jessica Snead, Maria T. DeSancho , et al. · 2024

Patients with acquired haemophilia A (PwAHA) can present with severe bleeding and may require lengthy treatment with bypassing agents and immunosuppression. We present two cases of the implementation of emicizumab in PwAHA. The first patie…

Predictors of thrombosis during VV ECMO: an analysis of 9809 patients from the ELSO registry Open

Tia C. L. Kohs, Benjamin R. Weeder, Boris I. Chobrutskiy, Thomas Kartika, Kerry Moore , et al. · 2023

Issue Information Open

Corinne LaVasseur, Rick C. Mathews, J Wang, Koen Martens, Hannah Stowe McMurry , et al. · 2023

Transfusion requirements and complication rate in β-thalassemia intermedia due

Issue Information Open

Marc A. Pfeffer, Koen Martens, Thomas Kartika, Hannah Stowe McMurry, Steven T. Olson , et al. · 2023

Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia

Estrogen‐based hormonal therapy and the risk of thrombosis in <span>COVID</span>‐19 patients Open

Corinne LaVasseur, Rick Mathews, Jenny Wang, Kylee L. Martens, Hannah Stowe McMurry , et al. · 2023

Objective Estrogen‐containing contraceptives and hormone replacement therapy are used commonly, however, the risks of venous and arterial thrombosis imparted by such medications during COVID‐19 infection or other similar viral infections r…

Psychological toxicity in classical hematology Open

Michael Pfeffer, Kylee L. Martens, Thomas Kartika, Hannah Stowe McMurry, Sven R. Olson , et al. · 2023

Although considered “benign,” mild blood count abnormalities, genetic factors imparting inconsequential thrombotic risk, and low‐risk premalignant blood disorders can have significant psychological and financial impact on our patients. Sev…

Issue Information Open

Elizabeth Elliott, Robert Hensen, L. Haupt, Lyn R. Griffiths, Ajay Mohinani , et al. · 2023

RNA-binding protein PUM2 promotes T-cell acute lymphoblastic leukemia via competitively binding

Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer Open

Malinda West, Shaun Goodyear, Evthokia Hobbs, Andy Kaempf, Thomas Kartika , et al. · 2023

Background Cyclin-dependent kinase 4/6 inhibitors (CDKi) have changed the landscape for treatment of patients with hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER−) metastatic breast cancer (MBC). Howe…

Desmopressin as a hemostatic and blood sparing agent in bleeding disorders Open

Ajay Mohinani, Sarah Patel, Virginia Tan, Thomas Kartika, Sven R. Olson , et al. · 2023

Intranasal, subcutaneous, or intravenous desmopressin can be utilized to release von Willebrand Factor and Factor VIII into circulation, enhance platelet adhesion and shorten bleeding time. Due to these properties, desmopressin can be effe…

Real-World Comparison of Bleeding and Thrombotic Outcomes in V-V ECMO: Heparin Versus Bivalirudin Open

Thomas Kartika, Rick Mathews, Gina Migneco, Taylor Bundy, Andy Kaempf , et al. · 2023

Re: Hormonal therapies and venous thrombosis: The estrogen matters! Morimont et al. Open

Corinne LaVasseur, Joseph J. Shatzel, Thomas Kartika · 2023

The diagnosis and management of suspected lymphoma in general practice Open

Ashley Paquin, Emmanuella Oyogoa, Hannah Stowe McMurry, Thomas Kartika, Malinda West , et al. · 2022

With rapid advancements in diagnosis and treatment of malignancies, the gap between generalists and subspecialists continues to widen, particularly in cancers like lymphoma where the spectrum of disease varies from indolent to rapidly prog…

Hormonal therapies and venous thrombosis: Considerations for prevention and management Open

Corinne LaVasseur, Suvi Neukam, Thomas Kartika, Bethany Samuelson Bannow, Joseph J. Shatzel , et al. · 2022

Association of PD-L1 expression, tumor mutational burden and immunotherapy with venous thrombosis in patients with solid organ malignancies Open

Rajat Thawani, Thomas Kartika, Benjamin Elstrott, Elizabeth Batiuk, Derrick L. Tao , et al. · 2022

Thrombotic events in patients using cyclin dependent kinase 4/6 inhibitors, analysis of existing ambulatory risk assessment models and the potential influences of tumor specific risk factors Open

Malinda West, Thomas Kartika, Ashley Paquin, Erik Liederbauer, Tony J. Zheng , et al. · 2022

Assessing the risk of thromboembolism in cancer patients receiving immunotherapy Open

Abhishek Goel, A.A. Khorana, Thomas Kartika, Sonia Gowda, Derrick L. Tao , et al. · 2021

Malignancy has long been implicated with hypercoagulability, leading to an increased rate of both venous and arterial thromboembolic events (VTE and ATE). Immunotherapy has established itself as a cornerstone of modern cancer therapy by pr…

Comparison of Classification of Indications for Allogeneic and Autologous Transplant for Adults in ASTCT Guidelines and Evidence Available in Published Literature Open

Myung Sun Kim, Johnny Cai, Ashray Maniar, Thomas Kartika, Alyson Haslam , et al. · 2021

This cross-sectional study quantifies the number of randomized clinical trials in the literature for each indication for stem cell transplantation by disease type and status.

Thomas Kartika YOU? Author Swipe